Immuno-Oncology | Specialty

Dr. Lallas on Immunotherapy Combinations in Genitourinary Malignancies

May 22nd 2017

Costas Lallas, MD, professor at Sidney Kimmel Medical College, Thomas Jefferson University Hospital, discusses combinations of immunotherapy for genitourinary malignancies.

Lead Researcher Discusses FDA Approval of Pembrolizumab for Urothelial Carcinoma

May 22nd 2017

Arjun V. Balar, MD, discusses the impact of the approval of pembrolizumab and other immunotherapy agents in urothelial carcinoma, as well as the next steps with these treatments.

Future of Immunotherapy in Head and Neck Cancer May Be in Combinations

May 22nd 2017

Researchers are hoping to build on the success of the KEYNOTE-012 and CheckMate-141 trials, which led to the approvals of pembrolizumab and nivolumab, respectively, by examining anti–PD-1/PD-L1 agents in the frontline and as a part of combination regimens for patients with head and neck cancer.

ASCO 2017: Improving the Patient-Doctor Immunotherapy Discussion

May 22nd 2017

Ahead of this year's meeting, researchers are increasingly interested in the state of communication between patients and doctors on immunotherapy.

Dr. Greten on Promising Immunotherapy Agents in HCC

May 19th 2017

Tim F. Greten, MD, senior investigator thoracic and gastrointestinal oncology branch, head, gastrointestinal malignancy section, National Cancer Institute, discusses promising immunotherapy agents being investigated in hepatocellular carcinoma (HCC).

Dr. Petrylak on FDA Approval of Pembrolizumab in Bladder Cancer

May 18th 2017

Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and Urology, co-director, Signal Transduction Research Program, Yale Cancer Center, discusses the FDA approval of pembrolizumab (Keytruda) for the treatment of patients with bladder cancer.

FDA Approves Pembrolizumab for Urothelial Carcinoma

May 18th 2017

The FDA has granted pembrolizumab approvals in the frontline and second-line settings for urothelial carcinoma.

Dr. Black on Combinations with Durvalumab in Bladder Cancer

May 17th 2017

Peter Black, MD, senior research scientist, Vancouver Prostate Center, associate professor, Department of Urologic Sciences, University of British Columbia, discusses combination trials with durvalumab (Imfinzi) for patients with bladder cancer.

Dr. Gupta on VEGF Inhibitors Combined with Immunotherapy in Kidney Cancer

May 17th 2017

Shilpa Gupta, MD, assistant professor, Hematology Oncology and Transplantation Division, University of Minnesota, discusses combining VEGF inhibitors with immunotherapy for patients with kidney cancer.

Cleveland Clinic Researchers Explore Epigenetic Combo as Immunotherapy Booster

May 16th 2017

An epigenetic strategy under study at Cleveland Clinic combines THU, a cytidine deaminase inhibitor, with decitabine and nivolumab (Opdivo) in patients with non-small cell lung cancer. The results of early studies demonstrate that THU may help prime the immune system.

Dr. Corn on Possibility of Immunotherapy for Patients With Prostate Cancer

May 15th 2017

Paul G. Corn, MD, PhD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the possibility of immunotherapy in patients with prostate cancer.

Chemotherapy/Immunotherapy Combinations in Lung Cancer

May 12th 2017

The Changing Immunotherapy Landscape in Lung Cancer

May 12th 2017

Efficacy and Safety of Checkpoint Inhibitors in Lung Cancer

May 12th 2017

Maintenance Strategies in Lung Cancer

May 12th 2017

Lung Adenocarcinoma: The Evolving Role of Chemotherapy

May 12th 2017

Importance of Chemotherapy in Lung Cancer

May 12th 2017

Important Long-Term Considerations in Lung Cancer

May 12th 2017

Initial Treatment Approach in Lung Cancer

May 12th 2017

PD-L1 Status: What Is the Current Role?

May 12th 2017